The National Centre for Research and Development



CORE; Programme area: health; ID 199523



Project title: Nanoparticulate delivery systems for therapies against neurodegenerative diseases


Acronym: NanoNeucar


Project Promoter: Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences


Polish partners: Institute of Pharmacology Polish Academy of Sciences; Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University


Norwegian Partners: SINTEF Materials and Chemistry; Laboratory of Molecular Neuroscience at the University of Oslo


Project cost (EUR): 991 877


Grant amount (EUR): 954 862

Duration: 36 months






Project summary:  Prevention and treatment of neurodegenerative diseases and stroke-related brain damage are major and unresolved problems of contemporary medicine. Despite the progress in understanding of molecular mechanisms of neuronal injury and preventing them, only few neuroprotective substances are used in the clinic and their efficiency in the treatment of stroke and neurodegenerations is not satisfactory. One of the major limitations to current neurodegenerative disease treatment is an inefficient delivery of neuroprotective drugs to the affected part of the brain.

The blood-brain barrier (BBB) is permeable by small (< 1000 Da), lipophilic molecules only. When a neuroprotective drug enters the brain, it may be partially brought back to the capillary lumen by multidrug resistance proteins. Moreover, some of the orally delivered neuroprotective drugs may influence the whole organism, thus causing peripheral toxicity and numerous adverse reactions. The main project objective is to develop the new strategy of delivery of neuroprotectants by the nanocarriers, which are able to cross the blood-brain barrier without imposing side effect on its normal function. We will concentrate on developing various methodologies of encapsulation of neuroprotectants, adjusted to their physicochemical properties, for formation of nanocarriers with the size in the range (10 – 150 nm) and surfaces functionalized for targeted delivery. We will elaborate the mechanisms of internalization of nanocarriers of different structure and architecture of external layer in the “in vitro” models of BBB and in-vivo in wild type and transgenic mice models. The effects of some promising neuroprotectants and gene-delivery used in nanoparticulate formulations on viability of neuronal cells exposed to toxic agents will be examined. We hope that our nanocarriers will be used in future for therapies of stroke and neurodegenerative diseases as Alzheimer’s and Parkinson’s or schizophrenia.


The National Centre for Research and Development
47a Nowogrodzka Str.,  00-695 Warszawa  office: +48 22 39 07 401  fax: +48 22 20 13 408
REGON: 141032404  NIP: 701-007-37-77

realizacja: Ideo powered by CMS Edito